Medchemexpress LLC D18 | 2230218-36-5 | 98.79% | C21H28N6 | 25 MG

Supplier:  Medchemexpress LLC 25MGHY144501

D18 is an immune modulator and TLR7/8 dual agonist, enhancing PD-L1 expression via epigenetic regulation to increase tumor sensitivity to PD-1/PD-L1 blockade. It also serves as an ADC cytotoxin, exhibiting strong immune activation and anti-tumor activity, frequently used in cancer research, especially for colon cancer.

• Functions as a TLR7/8 dual agonist (EC50 = 24 nM for hTLR7, 10 nM for hTLR8).
• Increases tumor sensitivity to PD-1/PD-L1 blockade.
• Exhibits strong immune activation and anti-tumor activity.
• Frequently employed in cancer research, particularly for colon cancer.
• Elevates IFN-γ, TNF-α, IL-1β, IL-12 p40, and IP-10 in hPBMCs (in vitro).
• Inhibits tumor growth in BALB/c mice bearing CT26 tumors (in vivo).
• Increases immune cell penetration.
• Demonstrates good safety.

Catalog No. 50-003-55962